UBS Group »

Arrowhead Pharmaceuticals In Note 1/1 shares owned by UBS Group

Quarter-by-quarter ownership of Arrowhead Pharmaceuticals In Note 1/1 shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Arrowhead Pharmaceuticals In Note 1/1

Tip: Access up to 7 years of quarterly data

All positions including Arrowhead Pharmaceuticals In Note 1/1 held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrowhead Pharmaceuticals In Note 1/1 by UBS Group

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.3M 4.2M 1.03

More positions owned by UBS Group

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Amazon (AMZN)
Meta Platforms Cl A (META)
Spdr Gold Tr Gold Shs (GLD)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core Msci Eafe (IEFA)
Alphabet Cap Stk Cl C (GOOG)
Taiwan Semiconductor Manufac Sponsored Ads (TSM)
Ubs Group SHS (UBS)

View all positions for UBS Group

Top funds holding Arrowhead Pharmaceuticals In Note 1/1

Deerfield Management Company
Camden Asset Management
LMR Partners
Readystate Asset Management
Calamos Advisors
Context Capital Management
Bnp Paribas Arbitrage, Snc
Oaktree Capital Management
Polar Securities
Lazard Asset Management
Shenkman Capital Management
Point72 Asset Management
SSI Investment Management
Ing Investment Management
UBS Group

View all funds holding Arrowhead Pharmaceuticals In Note 1/1